tbuckley/cabot-search huggingface dataset:
AB0461 A Retrospective Study of Primary Sjogren's Syndrome Patients with Cancer in Chinese Population: A Single-Center Experience
Authors: J. Qi, Q. Li, Z. Hu, P. Zhang, Y. Jiang, Z. Chen, J. Gu
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> With the development of modern therapies, better care of patients with primary Sjogren9s syndrome has been achieved. However, primary Sjogren9s syndrome may share an association with risk of lymphoproliferative disease or other malignancy. <h3>Objectives</h3> To investigate the clinical features of primary Sjogren9s syndrome (pSS) patients with malignancies. <h3>Methods</h3> We studied clinical features of the pSS patients coexist with malignancies in the Third Affiliated hospital of Sun Yat-sen University from 2002 to 2015. Thirteen out of 918 patients with pSS developed malignancies, both solid tumors and lymphomas. Student9s t test was used to compare patients9age and age of onset. <h3>Results</h3> The ratio of pSS with malignancies was 1.4% (13/918) in these patients. 6 were lymphoma, including 5 diffuse large B-cell lymphoma (DLBCL) and one mucosa associated lymphoid tissue type (MALT) Lymphoma. 7 were solid tumors, including one Colon cancer, one Hepatocellular carcinoma, one cervical carcinoma, one ovarian cancer, and one breast cancer, one cervical lymph nodes of squamous cell carcinoma and one peritoneal metastasis of unknown origin. The onset age of pSS was 44.5±19years,and onset age of malignancies was 47±18.4years. it seems that the age of pSS patients with solid tumors (53.6±18.9 years) was older than the age of pSS patients with lymphoma (34±13.9 years),but there was no significant difference. <h3>Conclusions</h3> The most frequent cancer associated with pSS is Lymphomas. the age of pSS patients with solid tumors might be older than the age of pSS patients with lymphoma. <h3>References</h3> Theander, E.; Henriksson, G.; Ljungberg, O.; Mandl, T.; Manthorpe, R.; Jacobsson, L. T., Lymphoma and other malignancies in primary Sjogren9s syndrome: a cohort study on cancer incidence and lymphoma predictors. Annals of the rheumatic diseases 2006, 65 (6), 796–803. Boussios, S.; Pentheroudakis, G.; Somarakis, G.; Markatseli, T. E.; Drosos, A. A.; Pavlidis, N., Cancer diagnosis in a cohort of patients with Sjogren9s syndrome and rheumatoid arthritis: a single-center experience and review of the literature. Anticancer research 2014, 34 (11), 6669–76. <h3>Disclosure of Interest</h3> None declared
OC-074 Novel Point of Care Test for Detection of Human Phospholipase A2 to Predict Acute Pancreatitis Post Endoscopic Retrograde Cholangiopancreatography (ERCP) and Aid Same Day Discharge
Authors: N Phillips, M Tyreman, A Bentham, D Bansi, P Vlavianos, D Westaby, CA Wadsworth, SA Khan
Journal: Gut (2016)

<h3>Introduction</h3> ERCP is a therapeutic procedure which carries a 5% risk of pancreatitis. Most patients who have undergone ERCP are admitted overnight for observation as it can take up to 12 hours for post-ERCP pancreatitis to manifest. Phospholipase A2 Group IB (PLA2GIB) is a sensitive marker of pancreatitis. A rapid, quantitative, point-of-care (POC) test for PLA2GIB has been developed.<sup>1</sup> We aimed to apply this test in a clinical setting, and determine its ability to detect clinically significant episodes of post-ERCP pancreatitis. <h3>Methods</h3> Ethical approval for the study and informed patient consent were obtained. Patients undergoing ERCP were randomly selected within a tertiary referral HPB centre. Blood amylase levels were obtained before and 3 hrs after ERCP. At the same times, 20µL of blood was taken, added to a running buffer and applied to the POC kit. Movement of the diluent was observed along the lateral flow strip. The lateral flow strip was then read by a micro device, calculating the PLA2GIB concentration from a standard curve. Cases of post ERCP pancreatitis were idenitified on the basis of characteristic pain, examination findings and elevation in serum amylase. <h3>Results</h3> 46 patients undergoing ERCP were recruited (26 M). Indication for ERCP included biliary stones (21), biliary strictures (12), biliary stent removal (6), pancreatic duct intervention (2) and other (5). The median pre-ERCP amylase level was 52 IU/L (range 19–316). The median post ERCP amylase was 78 IU/L (32–1720). Median pre-ERCP PLA2GIB concentration was 4 ng/mL (0.5–45). Median post-ERCP PLA2GIB was 6 ng/mL (0.6–418). There was a median 0.3 fold (-0.7-29) increase in PLA2GIB concentration after ERCP. 3 patients developed post-ERCP pancreatitis. These patients all had corresponding elevations in PLA2GIB above 70 ng/mL. A further 3 patients had elevation of amylase &gt;3 x the upper limit of normal but without clinical symptoms of pancreatitis and with a PLA2GIB level &lt;70 ng/mL. With a cut off level of 70 ng/mL, PLA2GIB had a sensitivity of 100% and specificity of 98%. The PPV was 75% and NPV 100%. <h3>Conclusion</h3> This is the first clinical trial of a POC test for PLA2GIB activity. The test appears to be highly sensitive for post-ERCP pancreatitis. In our cohort of 46 patients undergoing ERCP, a negative test at 3 hours would have reliably excluded all cases of post-ERCP pancreatitis. This low cost, easy to use POC test could be used to support same day discharge of patients undergoing ERCP. <h3>Reference</h3> 1 Chapman R, <i>et al</i>. Multivalent nanoparticle networks enable point-of-care detection of human phospholipase-A2 in serum. <i>ACS Nano</i> 2015;2565–2573. <h3>Disclosure of Interest</h3> None Declared
Genetic Linkage of the Dehydrated Hereditary Stomatocytosis Locus to Chromosome 16 in Two Kindreds and Refinement of the Candidate Gene Region to 16q24.2 - 16qter,
Authors: Brett L. Houston, Teresa Zelinski, Donald S Houston, Sara J. Israels, Gail Coghlan, Bernie N. Chodirker, Patrick G. Gallagher, Ryan Zarychanski
Journal: Blood (2011)
PWE-038 Validation of Multiparametric MRI in The Assessment and Staging of Non-Alcoholic Fatty Liver Disease: Abstract PWE-038 Table 1
Authors: P Eddowes, N McDonald, N Davies, S Semple, S Hübscher, T Kendall, C Kelly, M Mavar, A Herlihy, P Newsome, S Olliff, J Fallowfield, G Hirschfield
Journal: Gut (2016)

<h3>Introduction</h3> Hepatic fibrosis is an important determinant of outcome in non-alcoholic fatty liver disease (NAFLD). The severity of non-alcoholic steatohepatitis (NASH) has relevance to clinical follow up intensity and assessment of the effectiveness of treatment interventions. Magnetic resonance imaging (MRI)-acquired T1 measurement has been shown to correlate with hepatic fibrosis and is also increased by inflammation, indicating potential as a tool to stratify NAFLD. <h3>Methods</h3> Patients undergoing liver biopsy (LB) were invited for MRI and blood sampling prior to LB. Iron accumulation has been shown to reduce T1 independent of fibrosis, so an iron corrected hepatic T1 (cT1) was calculated using LiverMultiscan (Perspectum Diagnostics, Oxford). Histology was graded by two expert liver histopathologists according to the NASH-CRN system. <h3>Results</h3> 50 patients had complete data sets following exclusions (1 inadequate biopsy, 3 MRI data unavailable). 28 (56%) patients were male. Median age 54 years. 26 (52%) patients had type-2 diabetes. Mean (±SD) body mass index was 33.6 (±5.1) Kg/m2. Median (IQR) of ALT, fasting glucose and cholesterol were 54 (52) u/L, 6.2 (4.0) mmol/L and 4.8 (1.5) mmol/L, respectively. 38 (76%) LBs demonstrated NASH and the remainder simple steatosis (SS). Mean(±SD) cT1 for NASH and SS were 1007(±95) milliseconds (ms) and 907(±120) ms, respectively (p = 0.004). The correlation between cT1 and NAS was highly significant (Rho = 0.51, p &lt; 0.0001). To differentiate NASH from SS, cT1 had an AUROC (95%CI) of 0.71 (0.53–0.89). To diagnose significant (&gt;F1) and advanced (&gt;F2) fibrosis cT1 had an AUROC (95% CI) of 0.65 (0.48–0.83) and 0.62 (0.47–0.78), respectively. To identify patients with SS and no significant fibrosis cT1 had an AUROC (95%CI) of 0.75 (0.56–0.93). <h3>Conclusion</h3> Multiparametric MRI using LiverMultiscan has the ability to non-invasively stage fibrosis in patients with NAFLD. The additional benefit of this novel technology is the ability to concurrently establish the severity of NASH. The correlation of cT1 and NAS suggests that multiparametric MRI has potential for monitoring the effectiveness of treatment interventions in NAFLD. <h3>Disclosure of Interest</h3> P. Eddowes: None Declared, N. McDonald: None Declared, N. Davies: None Declared, S. Semple: None Declared, S. Hübscher: None Declared, T. Kendall: None Declared, C. Kelly Employee of: Perspectum Diagnostics, M. Mavar Employee of: Perspectum Diagnostics, A. Herlihy Employee of: Perspectum Diagnostics, P. Newsome: None Declared, S. Olliff: None Declared, J. Fallowfield: None Declared, G. Hirschfield: None Declared
FRI0616-HPR Cardiac Autonomic Response To Osthostatic Changes in fibromyalgia Sindrome: Table 1.
Authors: C.P. Andrade, A.R. Zamunér, M. Forti, E. Silva
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Patients with fibromyalgia syndrome (FMS) have autonomic nervous system (ANS) related disorder<sup>1</sup>. The orthostatic stimulus is an important method for the assessment of neurocardiac integrity<sup>2</sup>. However, little is known about the cardiac autonomic response to the active standing test in women with FMS. <h3>Objectives</h3> To evaluate the cardiac autonomic control response to the active standing test in women with FMS. <h3>Methods</h3> Ten women with FMS (FMSG n=10) and ten healthy women (HG n=10) took part in the study. The volunteers were submitted to the recording of RR intervals (RRi) during 15 min in supine and 15 min in orthostatic (active standing) positions. RRi were recorded by a heart rate monitor. The parameters of the frequency domain were determined by the heart rate variability (HRV) spectral analysis, obtained in low frequency (LF, 0.04–0.15 Hz) and high frequency bands (HF, 0.15–0.4 Hz) in normalized units (n.u.) and LF/HF ratio<sup>3</sup>. <h3>Results</h3> The results are shown in table 1. There were significant group x posture interaction for LF (n.u.) and HF (n.u.). Post hoc analysis revealed that the HG increased LF (n.u.) and decreased the HF (n.u.) during active standing, compared to the supine position. On the other hand, the FMSG presented no significant differences between supine and orthostatic position. Regarding between group comparisons, FMSG presented higher LF (n.u.) and lower HF (n.u.) at supine position. <h3>Conclusions</h3> FMSG showed cardiac autonomic dysfunction at supine position, characterized by higher sympathetic and lower parasympathetic cardiac autonomic modulation. In addition, FMSG present a blunted cardiac autonomic control response to the active standing, characterized by a lack of cardiac sympathetic modulation increase and parasympathetic decrease. Therefore, the neurocardiac integrity seems to be compromised in the FMSG. <h3>References</h3> Zamunér AR, Forti M, Andrade CP, Avila MA, Silva E. Respiratory Sinus Arrhythmia and its Association with Pain in Women with Fibromyalgia Syndrome. 2015 a.[Epub ahead of print]. Furlan R, Colombo S, Perego F, Atzeni F, Diana A, Barbic F, et al. Abnormalities of cardiovascular neural control and reduced orthostatic tolerance in patients with primary fibromyalgia. J Rheumatol. 2005;32:1787–1793. Task Force. Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task force of the European society of cardiology and the North American Society of pacing and electrophysiology. Circulation. 1996;93:1043–1065. <h3>Acknowledgement</h3> This study was supported São Paulo Research Foundation (FAPESP), grants #2011/22122–5, #2013/17504–1 and 2015/23449–9 and by the National Council for Scientific and Technological Development (CNPq), grants no. 483032/2012–3 and 307187/2013–6. <h3>Disclosure of Interest</h3> None declared
Discontinuing noninvasive ventilation in severe chronic obstructive pulmonary disease exacerbations: a randomised controlled trial
Authors: Jacobo Sellares, Miquel Ferrer, Antonio Anton, Hugo Loureiro, Carolina Bencosme, Rodrigo Alonso, Pilar Martinez-Olondris, Javier Sayas, Patricia Peñacoba, Antoni Torres
Journal: European Respiratory Journal (2017)

We assessed whether prolongation of nocturnal noninvasive ventilation (NIV) after recovery from acute hypercapnic respiratory failure (AHRF) in chronic obstructive pulmonary disease (COPD) patients with NIV could prevent subsequent relapse of AHRF. A randomised controlled trial was performed in 120 COPD patients without previous domiciliary ventilation, admitted for AHRF and treated with NIV. When the episode was resolved and patients tolerated unassisted breathing for 4 h, they were randomly allocated to receive three additional nights of NIV (n=61) or direct NIV discontinuation (n=59). The primary outcome was relapse of AHRF within 8 days after NIV discontinuation. Except for a shorter median (interquartile range) intermediate respiratory care unit (IRCU) stay in the direct discontinuation group (4 (2–6) versus 5 (4–7) days, p=0.036), no differences were observed in relapse of AHRF after NIV discontinuation (10 (17%) versus 8 (13%) for the direct discontinuation and nocturnal NIV groups, respectively, p=0.56), long-term ventilator dependence, hospital stay, and 6-month hospital readmission or survival. Prolongation of nocturnal NIV after recovery from an AHRF episode does not prevent subsequent relapse of AHRF in COPD patients without previous domiciliary ventilation, and results in longer IRCU stay. Consequently, NIV can be directly discontinued when the episode is resolved and patients tolerate unassisted breathing.
TSLP-Induced Alterations of Multiple Signaling Pathways in Primary CRLF2 B-ALL Xenografts
Authors: Parveen Shiraz, Olivia Francis, Ineavely Delgado, Shannalee R Martinez, Jacqueline Coats, Katherine Salcedo Conception, Karina Mayagoitia, Elizabeth Ginelli, Terry-Ann Milford, Ross Fisher, Christopher L. Morris, Xiao-bing Zhang, Ruijun Su, Sinisa Dovat, Kimberly J Payne
Journal: Blood (2014)
Prognostic Significance of CD20 in Children with B-Precursor Acute Lymphoblastic Leukemia.
Authors: Sima Jeha, Cheng Cheng, John Sandlund, Raul Ribeiro, Bassem Razzouk, Jeffrey Rubnitz, Nobuko Hijiya, Scott Howard, Fred Behm, Ching-Hon Pui
Journal: Blood (2005)
Volunteer Unrelated Donor PBSC Collection Efficacy and Recipient Outcomes: Results of a Prospective National Marrow Donor Program (NMDP) Trial, 1999–2003.
Authors: Michael Pulsipher, Pintip Chitphakdithai, John Klein, Seira Kurian, Susan Leitman, Paolo Anderlini, Brent Logan, Mary M. Horowitz, Dennis L. Confer
Journal: Blood (2006)
Utility of FDG-PET in Post Transplant Lymphoproliferative Disorders: An Update from a Single Center Experience
Authors: Erika Ravelli, Valentina Mancini, Livio Gargantini, Chiara Rusconi, Claudia Maria Basilico, Mauro Turrini, Vittorio Ruggiero Zilioli, Denis Ciapanna, Giuliana Muti, Claudio Rossetti, Annamaria Nosari, Enrica Morra
Journal: Blood (2008)
PTH-004 Video Capsule Colonoscopy in Routine Clinical Practice
Authors: E Toth, A Nemeth, G Wurm Johansson, A Koulaouzidis, H Thorlacius
Journal: Gut (2016)

<h3>Introduction</h3> Colonoscopy is the gold standard in the work-up of patients(pts) with suspected colon pathology. However, conventional colonoscopy is an invasive procedure, associated with certain risks/adverse events and/or occasionally contraindicated. We report routine clinical experience with videocapsule colonoscopy(VCC), in pts with suspected colon pathology, from a tertiary referral centre in Sweden. <h3>Methods</h3> 77(20 M/57 F) consecutive pts (median age 56;range 15–89 yrs) with suspected colon pathology were included. PillCam®COLON 1/2 VCC(Given®Imaging Ltd) was used. Bowel preparation advised was 1 day of clear liquid diet, followed by a split-dose administration of polyethylene glycol (3+1 L); in order to enhance gastric &amp; small-bowel transit(SBT) and maximise mucosal visualisation, domperidone(40 mg) and/or on-demand sodium phosphate(30+15 ml) and bisacodyl(10 mg) suppository were administered. <h3>Results</h3> Reasons for VCC were previously incomplete and/or declined colonoscopy in 39 &amp; 26 pts, respectively; clinical indications were GI bleeding:28 (36%); suspected inflammatory bowel disease(IBD) or followup in patients with known IBD:23 (30%); and other (colorectal cancer screening, follow up of abnormal radiology &amp; diverticulitis):26 (34%) pts. 58/77 pts (75%) underwent a complete examination of the colon (median colon transit time was 257; range 3–895 min). In 3 cases the capsule did not reach the colon due to stomach retention, small-bowel (stricture) retention &amp; slow SBT. In the remaining 16 incomplete cases the capsule reached the rectum (n = 4), sigmoid (n = 6), descending (n = 5) and transverse colon (n = 1). Good or excellent bowel preparation was achieved in 58 (75%) pts. The most frequent findings were diverticulosis (29 pts, 38%); polyps (17 pts, 22%; size 3–20 mm); active IBD (12 pts, 16%); haemorrhoids (8 pts, 10%); angioectasia (4 pts, 5%) &amp; advance cancer (1 pt, 1%). 15 (19%) pts had no observable colon pathology. Pathological changes in the small-bowel were detected in 8 (10%) pts, including stricture, angioectasia, tumour &amp; Crohn’s lesions. All patients tolerated the bowel preparation and the VCC well. Two patients with significant pathology (ulcerated small-bowel stricture and colonic cancer) experienced a temporary capsule retention with spontaneous resolution. <h3>Conclusion</h3> VCC is an effective and well-tolerated method to examine the colon. Although further technical development may be needed to examine the whole colon in large numbers of patients, VCC may complement or even replace conventional colonoscopy for certain clinical indications. <h3>References</h3> 1 Spada C, <i>et al</i>. Second-generation PillCam® Colon Capsule Compared with Colonoscopy. <i>GIE.</i> 2011;<b>74</b>:581–9 2 Spada C, <i>et al</i>. Colon capsule endoscopy: ESGE Guideline. <i>Endoscopy.</i> 2012;<b>44</b>:527–36 <h3>Disclosure of Interest</h3> None Declared
Genomic Profiling Reveals Gain of Mutations in Histone Methylation Regulators in Relapsed Adult B Cell Precursor ALL
Authors: Lorenz Bastian, Martin Neumann, Nicola Gökbuget, Cornelia Schlee, Jutta Ortiz Tanchez, Sebastian Vosberg, Alva Rani James, Michael P Schroeder, Stefan Schwartz, Dieter Hoelzer, Alexander Graf, Stefan Krebs, Helmut Blum, Jochen Hecht, Monika Brüggemann, Philipp A. Greif, Claudia D. Baldus
Journal: Blood (2015)
AB0522 On The Possible Protective Role of Complement System in Immune Complex Lupus Nephropathy
Authors: V.I. Shishkin, Y.A. Malenkov, V.V. Shishkin, G.V. Kudriavtseva
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> The links between complement and SLE are complicated and fascinating. After many years of study, hypotheses are developing which may begin to explain these apparent paradoxical findings. <h3>Objectives</h3> To assess correlation between complement? Circulating immune complexes and organ pathology in SLE. <h3>Methods</h3> Of 277 patients enrolled, 252 were female (91%) and the mean age of the patients was 46.6 years (range 18 to 70). 194 patients (70%) had active disease defined as SLEDAI score. All patients met ≥4 ACR SLE criteria. Complement activity in serum was detected by hemolytic method in CH50 units. For the assay of immune complexes (CIC), polyethylene glycol (PEG) precipitation method was used. As a control we used sera from 100 healthy donors. <h3>Results</h3> During a long observation of SLE patients we identified variants of hypocomplementemia dynamics. In the group 1 there was almost continuous and increasing hypocomplementemia (75 patients). In the group 2 hypocomplementemia arose during exacerbation of the disease and the complement level was restored under the influence of treatment (67 patients). In the group 3, the activity of complement constantly corresponded to the normal level (135 patients). Glomerulonephritis was diagnosed in 50% of patients in the first group and 46% in the 2nd and in 35.3% in the third group. Renal failure was more frequent among patients in groups 1 and 2. In the group 3, it appeared significantly less often, because of long course of the disease. The average activity of the complement, depending on the group of patients differed, and the average concentration of CIC was highest in the group 3 and in groups 1 and 2 it was statistically less high and was almost the same in both groups. However, signs of inflammation, such as fever and ESR, CRP were higher in patients of the group 3. The activity of complement was the most low and CIC levels were high in patients with renal insufficiency. A decrease of complement activity in patients with the maximum degree of activity of SLE in 56% and 57%, respectively. When calculating the number of units of CH50 per number of units of CIC we get a new integral indicator of the activity of the disease in more than 89% of cases. <h3>Conclusions</h3> According to the activity of the complement system in SLE represents a heterogeneous group. The low level of activity of the complement system, characteristic for a certain group of patients contributes to the appearance of glomerulonephritis. High level of complement has a protective effect against renal pathology. The ratio of activity of the complement system and the level of circulating immune complexes has a specific pathogenic role in SLE. <h3>Disclosure of Interest</h3> None declared
PTH-090 Eosinophilia of The Gut. Is It Inflammatory Bowel Disease?
Authors: S Chetcuti Zammit, J Gauci, M Cachia, K Sapiano, P Ellul
Journal: Gut (2016)

<h3>Introduction</h3> Eosinophilic gastroenteropathy (EG) is an uncommon condition. The causes for this can be numerous as well as non-specific. Inflammatory Bowel Disease (IBD) is one of the causes. It can also be a manifestation of atopy. The aims of our study were (1) to determine if patients who present with eosinophilia of the gut are eventually diagnosed with IBD and (2) to determine if patients with EG have a higher rate of atopic conditions namely, asthma, allergic rhinitis and eczema. <h3>Methods</h3> Adult patients who had gastrointestinal eosinophilia were identified through the histopathology department and recruited. Their clinical case notes were reviewed. Patients were interviewed and asked questions regarding asthma, allergic rhinitis and eczema. <h3>Results</h3> 66 patients (39 females; mean age 48.4 SD±18.5) were recruited. The mean eosinophilic count was 0.353 SD±1.08 (normal range 0.10–0.70 x 10 9/L).The commoner clinical presentations were diarrhoea (42.4%), abdominal pain (33.3%) and weight loss (8.2%). The parts of the gastrointestinal tract where eosinophilic infiltration was present were: stomach (6), colon (37), small bowel (SB) (7), SB and colon (12), oesophgeal (1), oesophageal and colon (2), stomach, SB and colon (1).25.8% of patients were later diagnosed with IBD (10 patients - ulcerative colitis, 6 patients – Crohn’s disease and 1 patient had indeterminate colitis). No other secondary causes for GE were present in the rest of the patients and their symptoms resolved without any medical intervention.The prevalence of allergic rhinitis (41.3%) (p &lt; 0.002) and eczema (26.1%)(p &lt; 0.001) with GE were higher than that of the general population. Although asthma (17.4%) was more frequently present in patients with GE than the population, this did not reach statistical significance (p &lt; 0.62). <h3>Conclusion</h3> A high proportion of patients (25.8%) with GE was subsequently diagnosed with IBD. Asthma, eczema and allergic rhinitis in patients with underlying EG are higher than in the general population. Most of the patients had transient GI symptoms that later resolved. Thus, GE may represent an atopic condition of the gut or a response to a food allergen. <h3>Disclosure of Interest</h3> None Declared